provider about low blood sugar and how to manage it. Tell your healthcare provider if you are taking medicines to treat diabetes including an insulin or sulfonylurea.- Your healthcare provider should show you how to use Zepbound before you use it for the first time.Review these questions with your healthcare provider: Do you have other medical conditions, including problems with your pancreas, or severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting ...

An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York on March 28, 2024.Eli Lilly on Monday launched a new form of its blockbuster obesity drug, Zepbound, that offers a month's worth of doses in a single pen.Cash-paying patients can get the multi-dose device, called KwikPen, on the company's direct-to-consumer website, LillyDirect. Prices start at $299 per month for the lowest dose level. The pen could serve as a more convenient option for some patients, as it reduces the nu ...

Financial Data and Key Metrics Changes - In the first quarter of fiscal year 2026, the company generated approximately $261 million in revenue, reflecting a 0.3% decline year-over-year on an as-reported basis, or a 2% decline on an adjusted constant currency basis [14] - GAAP gross profit and margin for the first quarter totaled $161.7 million and 61.9%, compared to $151.7 million and 60% in the prior year period [19] - GAAP net income and earnings per diluted share were $44.1 million and $0.74 during the first quarter, compared to $0 in the prior year period [21] Business Line Data and Key Metrics Changes - Adjusted constant currency pen needle revenue declined approximately 4.4%, while syringe revenue grew by approximately 5.3% and safety product revenue grew approximately 7.3% [17] - Contract manufacturing revenue declined approximately 16.7%, primarily due to the continued insourcing of these products by Becton Dickinson [17] Market Data and Key Metrics Changes - U.S. revenue for the quarter totaled approximately $131 million, reflecting a year-over-year decline of 7.6% on an adjusted constant currency basis, driven by lower pricing and lower volumes [15] - International revenue for the first quarter totaled approximately $130 million, representing an increase of 8.4% on a reported basis and an increase of 4.6% on an adjusted constant currency basis, driven by strength across EMEA and Latin America [16] Company Strategy and Development Direction - The company is focused on transitioning to a broader medical supplies company and drug delivery partner, with a strong emphasis on brand transition and portfolio expansion [6][7] - The company aims to strengthen its core business while selectively expanding its portfolio in areas that leverage existing strengths, particularly in the Medicare Part D channel [9][10] Management's Comments on Operating Environment and Future Outlook - Management expects the recovery in China to be more weighted towards the second half of the fiscal year, given ongoing market dynamics and geopolitical factors [16] - The company reaffirmed its financial guidance for the year, now expecting to be closer to the lower end of the guidance ranges due to incremental U.S. pricing headwinds [18][25] Other Important Information - The company is advancing its GLP-1 strategy, collaborating with over 30 pharmaceutical partners, with initial generic GLP-1 launches anticipated in markets such as Canada, Brazil, China, and India beginning in calendar year 2026 [11][12] - The company generated approximately $17 million in free cash flow during the first quarter and repaid approximately $38 million of outstanding debt, reducing its net leverage level to approximately 2.8 times [23][24] Q&A Session Summary Question: Can you provide insights on U.S. business dynamics, pricing impacts, and the expected recovery in China? - Management noted a year-over-year decline in the U.S. driven by lower pricing and volume, with channel dynamics impacting results. They expect a recovery in China in the second half of the year [30][32] Question: What factors contributed to the strength in international markets? - Management attributed the growth in international markets to superior execution, particularly in Latin America, where a new large customer has driven growth [43] Question: Can you elaborate on the GLP-1 opportunity and the impact of oral therapies? - Management remains confident in the GLP-1 opportunity, noting that injectables have better weight loss profiles and that the market for orals is expanding rather than pulling patients away from injectables [36][38]